Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Munich - Delayed Quote EUR

Clearside Biomedical, Inc. (CLM.MU)

Compare
0.8300
-0.0300
(-3.49%)
At close: April 4 at 8:00:38 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CLM.MU

Recent News: CLM.MU

View More
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com 3 days ago
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire 4 days ago
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations

Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations
Simply Wall St. 7 days ago
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
Zacks 8 days ago
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire 8 days ago
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
GlobeNewswire 12 days ago
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
GlobeNewswire 16 days ago
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
GlobeNewswire 24 days ago
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
GlobeNewswire 30 days ago
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?

Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
Zacks last month
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
GlobeNewswire last month
View More

Related Tickers

AVTE Aerovate Therapeutics, Inc.
2.4900
-0.80%
 
CGEM Cullinan Therapeutics, Inc.
7.41
-1.07%
 
ORIC ORIC Pharmaceuticals, Inc.
4.8800
-7.22%
 
ALXO ALX Oncology Holdings Inc.
0.5159
-3.23%
 
ZNTL Zentalis Pharmaceuticals, Inc.
1.1700
-8.95%
 
KYMR Kymera Therapeutics, Inc.
22.07
-6.84%
 
KROS Keros Therapeutics, Inc.
9.98
-2.92%
 
DAWN Day One Biopharmaceuticals, Inc.
7.22
-6.36%
 
BMEA Biomea Fusion, Inc.
2.1200
+8.72%
 
GMAB Genmab A/S
18.39
-4.42%